News
MYGN
21.32
-0.37%
-0.08
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
NASDAQ · 20h ago
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Myriad Genetics, Inc. (NASDAQ:MYGN) has US$38.5m in debt. The company lost US$263m in the last year, but managed to grow its revenue by 11%. Myriad Genetics has more cash than debt, and has a healthy balance sheet. We look at the debt levels of the company to see if it is risky. We've identified 1 warning sign with myriad Genetics.
Simply Wall St · 1d ago
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
NASDAQ · 1d ago
Weekly Report: what happened at MYGN last week (0318-0322)?
Weekly Report · 4d ago
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics, Inc. Issued a patent that will strengthen its ability to deliver a tumor-informed, molecular residual disease assay to market. The company is a leader in genetic testing and precision medicine. The U.S. Patent and Trademark Office has issued the patent.
Barchart · 03/21 20:40
Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
Benzinga · 03/20 20:08
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics, Inc. Granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. The U.S. Patent and Trademark Office has granted the patent. Myriad Genetics is a leader in genetic testing and precision medicine.
Barchart · 03/20 15:05
Myriad Genetics: Statement of changes in beneficial ownership of securities
Press release · 03/18 22:23
Weekly Report: what happened at MYGN last week (0311-0315)?
Weekly Report · 03/18 09:11
Weekly Report: what happened at MYGN last week (0304-0308)?
Weekly Report · 03/11 09:11
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
TipRanks · 03/06 12:36
Weekly Report: what happened at MYGN last week (0226-0301)?
Weekly Report · 03/04 09:11
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
NASDAQ · 03/01 14:41
Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty
TipRanks · 03/01 06:03
Myriad Genetics Full Year 2023 Earnings: EPS Misses Expectations
Myriad Genetics missed analyst estimates by 1.7%. The company's shares are down 5.7% from a week ago. Revenue was in line with analyst estimates. Revenue is forecast to grow 7.2% in the next 3 years. The company reported a loss of US$3.18 per share.
Simply Wall St · 02/29 19:19
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
NASDAQ · 02/28 12:50
Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TipRanks · 02/28 12:32
Myriad Genetics: A Sell Rating Amidst Profitability and Growth Concerns
TipRanks · 02/28 11:57
U.S. RESEARCH ROUNDUP-Autozone, Constellation Energy, Sterling Infrastructure
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Autozone, Constellation Energy, Sterling Infrastructure among companies with new targets. Analysts raise their ratings on several companies. Some of the companies include Acadia Pharmaceuticals, Bumble and Flywire.
Reuters · 02/28 07:20
Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook
TipRanks · 02/28 02:55
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.